CN Patent

CN105001207A — 制备喹诺酮类化合物的工艺

Assigned to Mai Linta Medical Treatment Co Ltd · Expires 2015-10-28 · 11y expired

What this patent protects

本发明涉及抗感染化合物的合成领域。特别地，本发明涉及用作抗感染试剂的喹诺酮类化合物的合成。本发明包括一种制备喹诺酮化合物的工艺，其中，产生的喹诺酮二聚物杂质低于约0.40％。

USPTO Abstract

本发明涉及抗感染化合物的合成领域。特别地，本发明涉及用作抗感染试剂的喹诺酮类化合物的合成。本发明包括一种制备喹诺酮化合物的工艺，其中，产生的喹诺酮二聚物杂质低于约0.40％。

Drugs covered by this patent

delafloxacin-meglumine (DELAFLOXACIN MEGLUMINE)

Patent Metadata

Patent number: CN105001207A
Jurisdiction: CN
Classification: —
Expires: 2015-10-28
Drug substance claim: No
Drug product claim: No
Assignee: Mai Linta Medical Treatment Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.